Effect of donor-specific antibodies and panel reactive antibodies in living donor liver transplant recipients by 二쇰쭔湲� et al.
100
pISSN 2288-6575 •  eISSN 2288-6796
http://dx.doi.org/10.4174/astr.2015.88.2.100
Annals of Surgical Treatment and Research
ORIGINAL ARTICLE
Effect of donor-specific antibodies and panel reactive 
antibodies in living donor liver transplant recipients
Seung Hwan Song1, Myoung Soo Kim1,2, Jung Jun Lee3, Man Ki Ju1,2, Jae Geun Lee1,2, Juhan Lee1,2,  
Jin Sub Choi1,2, Gi Hong Choi1,2, Soon Il Kim1,2, Dong Jin Joo1,2
1Department of Surgery and 2The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, 
3Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea
INTRODUCTION
Highly sensitized organ recipients are at greater risk of acute 
rejection, vascular complications, and poor graft survival [1-3]. 
Circulating donor-specific antibodies (DSAs) immunologically 
challenge the vascular endothelium and bile duct [4], but the 
liver is uniquely able to neutralize antibodies and escape from 
immunologic challenges [5,6]. However, the effects of DSAs 
on graft function and survival after liver transplantation 
remains controversial. Some authors suggest that a positive T 
lymphocyte cross match results in poor graft survival and more 
acute rejection [7,8], whereas others conclude that a positive T 
lymphocyte cross match has no effect on graft outcome [9,10]. 
Additionally, the role of circulating preformed DSAs before liver 
transplantation is unclear. Consequently, the aim of this study 
was to determine if preformed circulating DSAs negatively 
affect graft outcome after living donor liver transplantation 
(LDLT).
METHODS
The medical records of 219 adult LDLT patients that un-
Purpose: Preformed circulating donor-specific antibodies (DSAs) immunologically challenge vascular endothelium and 
the bile duct. However, the liver is an immune-tolerant organ and can avoid immunological challenges. This study was 
undertaken to analyze the effects of DSAs after adult living donor liver transplantation (LDLT). 
Methods: We retrospectively reviewed 219 LDLT patients’ records treated at our center. 
Results: Of the 219 patients, 32 (14.6%) were DSA (+) and 187 (85.4%) were DSA (–). Class I DSAs were present in 18 
patients, class II in seven patients, and both in seven patients. Seven patients (3.2%) showed DSA to HLA-A, four (1.8%) to 
HLA-B, seven (3.2%) to HLA-DR, and 14 (6.4%) to two or more HLAs. More DSAs were observed in female recipients than 
male recipients in the DSA (+) group. The DSA (+) group showed significantly higher levels of class I and II panel reactive 
antibody (PRA) than did the DSA (–) group. No significant intergroup differences were found between incidences of primary 
nonfunction, acute rejection, vascular complication, or biliary complication. There were no significant differences in graft 
survival rates between the two groups. However, the recipients with multiple DSAs tended to have more acute rejection 
episodes and events of biliary stricture and lower graft survival rates than did patients in the DSA (–) group. 
Conclusion: In LDLT, the presence of multiple DSAs and high PRA seemed to be associated with poor graft outcomes, 
although our results did not reach statistical significance. Large cohort studies are necessary to clarify the impact of DSA 
and PRA in LDLT.
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derwent treatment at Yonsei University College of Medicine 
between June 2006 and August 2012 were retrospectively 
reviewed. Pediatric and second transplant cases were excluded. 
Patients were allocated to two groups according to the presence 
of DSA. DSAs were identified by panel reactive antibody (PRA) 
identification conducted by ELISA using the Lambda Cell Tray 
lymphocytotoxicity assay (One Lambda Inc., Canoga Park, CA, 
USA). Records were reviewed for clinical and immunological 
characteristics, acute rejection episodes, complications, and 
graft survival. 
The primary immunosuppressive therapy used posttrans-
plant was a tacrolimus-based agent. Induction therapy with 
interleukin-2 receptor antibody (basiliximab) was used, except 
in cases with identical HLA matching. Antimetabolite was 
used depending on patient condition and side effects after 
transplantation. 
Continuous variables are presented as mean ± standard 
de viation and were analyzed using the two-tailed Student t- 
test or analysis of variance. Categorical variables, presented 
as proportions, were analyzed using Fisher exact test. Graft 
sur vival rates were calculated using the Kaplan-Meier method 
and compared among the groups using the log-rank test. Cox 
regression analysis was used to evaluate risk factors for graft 
survival. P-values of <0.05 were considered significant.
RESULTS
The mean follow-up time for the 219 study subjects was 28.3 
± 23.6 months posttransplantation. Mean patient age was 52.4 
± 7.7 years and there were 170 male and 49 female recipients. 
Liver transplantation indications consisted of 60 cases of 
B-viral cirrhosis (27.4%), 4 of C-viral cirrhosis (1.8%), 16 of 
alcoholic cirrhosis (7.3%), 4 of autoimmune cirrhosis (1.8%), 3 of 
cryptogenic cirrhosis (1.4%), 1 of primary biliary cirrhosis (0.5%), 
1 of primary sclerosing cholangitis (0.5%), 2 of metabolic liver 
disease (0.9%), 6 of acute liver failure (2.7%), 1 of other cirrhosis 
(0.5%), and 121 cases of hepatocellular carcinoma (55.3%). 
Among the 219 recipients, 32 recipients (14.5%) were positive 
for DSAs against donor HLAs by PRA. Of these 32 DSA positive 
(DSA (+)) recipients, DSAs for HLA class I (HLA A– or B–) were 
detected in 25 patients, DSAs for HLA class II (HLA DR–) in 
14 patients, and DSAs for both HLA class I and II in seven 
recipients. Of the 32 DSA (+) patients, 7 recipients had a single 
DSA for HLA-A (21.9%), 4 showed a single DSA for HLA-B (12.5%), 
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Table 1. Clinical characteristics and outcomes according to the presence of donor-specific antibodies
Characteristic DSA (−) (n = 187) DSA (+) (n = 32) P-value
Recipient age (yr) 52.1 ± 7.9 53.8 ± 6.4 NS
Recipient sex
   Male:female (female%) 157:30 (16.0%) 13:19 (59.4%) <0.001
MELD score 14.3 ± 8.4 15.3 ± 7.4 NS
Relation to donor 1 (0.5) 0 (0) NS
   Parent 119 (63.6) 23 (71.9)
   Offspring 26 (13.9) 3 (9.4)
   Sibling 11 (5.9) 3 (9.4)
   Distant relatives 11 (5.9) 0 (0)
   Volunteer 13 (7.0) 3 (9.4)
   Spouse 17 (9.1) 3 (9.4)
GRWR (%) 1.17 ± 0.25 1.28 ± 0.31 NS
Positive lymphocyte cross match 6 (3.2) 9 (28.1) <0.001
PRA class I (%) 4.7 ± 12.1 54.8 ± 12.1 <0.001
PRA class II (%) 0.9 ± 4.6 42.1 ± 39.3 <0.001
Acute rejection 14 (7.5) 3 (9.4) NS
Primary nonfunction 1 (0.5) 0 (0) NS
Vascular complications NS
   Hepatic artery thrombosis 5 (2.7) 0 (0)
   Portal vein thrombosis 5 (2.7) 0 (0)
   Portal vein stenosis 3 (1.6) 2 (6.3)
   Hepatic vein thrombosis 1 (0.5) 0 (0)
Biliary complications NS
   Anastomotic leakage 8 (4.3) 3 (9.4)
   Anastomotic stricture 47 (25.1) 7 (21.9)
Values are presented as mean ± standard deviation or number (%) unless otherwise indicated.
DSA, donor-specific antibody; MEDL, model for end stage liver disease; GRWR, graft to recipient weight ratio; PRA, panel reactive 
antibody; NS, not significant.
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7 showed a single DSA for HLA-DR (21.9%), and 14 showed two 
or more DSAs (43.7%), referred to as multiple DSA. 
According to the presence of DSAs, patients were divided 
into two groups, DSA (+) and DSA (–). There were more female 
patients in the DSA (+) group than in the DSA (–) group (59.4% vs. 
16.0%). T lymphocyte cross match positivity was more common 
in the DSA (+) group (28.1% vs. 3.2%), and the proportions of 
PRA class I and II were higher in the DSA (+) group. Other 
nonimmunologic factors, such as recipient age, model for end-
stage liver disease score, and donor-recipient relationship were 
similar between the two groups. In reviewing posttransplant 
complications, no significant intergroup differences were found 
for acute rejection episodes, primary non-function, vascular 
complications, or biliary complications (Table 1).
Recipients were subdivided into the following subgroups by 
type of DSA for HLA; the DSA (–) group, single DSA groups for 
HLA-A, -B, or -DR, and a multiple DSA group. Acute rejection, 
vascular complications, and biliary complications occurred at 
similar levels in these groups. However, the multiple DSA group 
had more acute rejection episodes and biliary anastomotic 
strictures than the other groups (Table 2); although, this was 
not statistically significant. 
Graft survival rates were not significantly different between 
the DSA (–) and (+) groups. One-year survivals in the DSA (–) 
and DSA (+) groups were 97.9 and 90.4%, respectively. Three-
year survival rates between DSA (–) and DSA (+) were 86.5% and 
85.7%, respectively (Fig. 1A). However, in the subgroup analysis, 
the multiple DSA group showed a lower graft survival rate than 
the DSA (–) or single DSA group, although this result was not 
statistically significant. One-year survival rates in the DSA free 
or single DSA group and multiple DSA group were 91.4% and 
85.7%, respectively, and corresponding 3-year survival rates were 
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Fig. 1. Graft survival rates according to the presence of donor-specific antibodies. (A) No difference in graft survival rates 
was found between the DSA (–) and (+) groups. (B) However, patients with multiple DSAs had a lower graft survival rate than 
patients in none or single DSA group. DSA, donor-specific antibody.
Table 2. Graft outcomes and complications according to numbers and types of donor-specific antibodies
Graft outcomes & complications DSA (−)(n = 187)
DSA (+) (n = 32)
P-value
A+ (n = 7) B+ (n = 4) DR+ (n = 7) Multiple (n = 14)
Acute rejection 14 (7.5) 0 (0) 0 (0) 0 (0) 3 (21.4) NS
Primary nonfunction 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) NS
Vascular complications NS
   Hepatic artery thrombosis 5 (2.7) 0 (0) 0 (0) 0 (0) 0 (0)
   Portal vein thrombosis 5 (2.7) 0 (0) 0 (0) 0 (0) 0 (0)
   Portal vein stenosis 3 (1.6) 1 (14.3) 0 (0) 0 (0) 1 (7.1)
   Hepatic vein thrombosis 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0)
Biliary complications NS
   Anastomotic leakage 8 (4.3) 0 (0) 0 (0) 3 (75.0) 0 (0)
   Anastomotic stricture 47 (25.1) 1 (14.3) 1 (25.0) 1 (25.0) 5 (35.7)
Values are presented as number (%).
DSA, donor-specific antibody; NS, not significant.
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85.8% and 75.0%, respectively (Fig. 1B). We divided all recipients 
into three groups; PRA < 10%, PRA 10%–30%, and PRA ≥ 30%. 
PRA class II ≥ 30% group showed worse graft survival rate than 
other groups but there was no significant difference among 
the group according to PRA class I and II. However, if the PRA 
percentages of class I and II were summed, PRA ≥ 30% group sh-
owed poorer graft survival rates than PRA 10%–30% group (Fig. 2). 
Recipient and donor age, graft to recipient weight ratio, 
gender mismatch, and multiple DSAs were analyzed as the risk 
factors for long-term graft survival. Cox regression analysis 
showed that there was no significant hazard ratio among the 
parameters (Table 3).
DISCUSSION
The liver is well known for its immune tolerance [11], and 
as such, liver transplantations have been performed on pa-
tients positive with a T lymphocyte cross match, with a 
HLA mismatch, and even patients with multiple DSAs [2,9]. 
Recently, Taner et al. [6] reported that DSA levels decreased 
at 1 week after liver transplantation in 17 of 20 recipients 
with pretransplant DSAs. Furthermore, they indicate that 
transaminase and bilirubin levels remain comparable during 
the first post-transplant year despite the presence of DSAs. 
Conversely, some reports show that HLA mismatch and DSAs 
cause poor graft survival and more acute rejection episodes 
[12,13]. Everly [14] suggested that all patients need to be 
monitored for DSA to identify new onset DSA or DSA clearance, 
and stressed that in all DSA scenarios, the treatment of 
persistent DSA is important, as it can improve allograft survival. 
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Fig. 2. Graft survival rates according to the percentage of panel 
reactive antibody (PRA). (A) Graft survival rates of the PRA ≥ 
30% group were lower than the PRA 10%–30% group (P = 
0.038) according to the sum of PRA percentage. No significant 
differences in graft survival rates were found among the PRA 
percentage groups according to the PRA classes I and II (B and C). 
However, class II showed more intervals among the groups. 
Table 3. Risk analysis for graft survival after liver transplan-
tation by Cox regression
Risk factor P-value Hazard ratio (95% CI)
Recipient age (yr) 0.418 0.980 (0.932–1.030)
Donor age (yr) 0.795 0.995 (0.956–1.035)
GRWR (%) 0.764 1.260 (0.279–5.694)
Gender mismatch 0.258 1.664 (0.689–4.021)
Multiple DSA 0.337 1.853 (0.526–6.520)
CI, confidence interval; GRWR, graft to recipient weight ratio; 
DSA, donor-specific antibody.
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In the current study, although statistical significance was not 
obtained, our results suggest that recipients with pretransplant 
multiple DSAs tend to have poorer graft outcomes than those 
with absent or single DSA, and that highly sensitized recipients 
should be monitored for antibody status after transplantation. 
Furthermore, we found that patients who had high class II PRA 
(≥30%) showed worse graft survival rates than those with lower 
class II PRA. Recent studies demonstrate that class II DSAs are 
associated with an increased risk of early rejection [15,16]. Our 
results suggest that class II DSAs may be more potent than class 
I DSAs. 
Given that this is a retrospective study, there are several li-
mitations inherent to this work. In particular, a relatively small 
number of patients were enrolled and no data was available 
regarding DSA status after liver transplantation. Because of the 
small number of patients, there were no significant risk factors 
for long-term graft survival in Cox regression analysis. Taner 
et al. [6] reported that the preformed DSA decreased after liver 
transplantation but remaining DSA affected the graft liver to a 
poor graft survival; however, this study did not show any post-
transplant change of DSAs. Further study is needed to clarify 
the findings reported herein. 
We did not perform a single antigen assay for detecting 
DSA and measurement of mean fluorescence intensity. Recent 
studies regarding DSA in liver transplantation show that high 
mean fluorescence intensity is related to poor graft outcomes 
and early acute rejection after liver transplantation [15,16]. The 
present study had no data regarding the mean fluorescence 
intensity of the DSA but showed that the number of DSAs 
is related with acute rejection and poor graft survival after 
liver transplantation. We suggest that not only the mean flu-
orescence intensity of DSA, but also the number of DSAs can be 
an important prognostic factor in LDLT.
Despite the limitations, this current study is important 
because it is the first to focus on DSA numbers in LDLT. Fur-
thermore, the study was conducted on LDLTs from strictly 
selected donors who exhibited relatively homogenous noni-
mmunologic conditions. The study design excluded various 
deceased donor factors such as ischemic time, steatosis, and 
age, which could themselves cause poor graft outcomes. 
A recent study showed that de novo DSA development after 
liver transplantation was an independent risk factor for poor 
graft outcomes [17]. They found that 8.1% of patients developed 
de novo DSA 1 year after transplantation, and almost all de 
novo DSAs were HLA class II antibodies. This result implies 
that we should carefully monitor not only pretransplant DSA 
but also DSA development status after liver transplantation. 
However, there was no definite follow-up protocol for de 
novo DSA after liver transplantation. In the current study, we 
showed multiple DSAs and high PRA over 30% could make 
for a worse prognosis than in other recipients. We carefully 
suggest that this kind of highly-sensitized recipient should be 
monitored for de novo DSA development within one year after 
transplantation. To make evidences, further studies will be 
needed. 
The present study showed that in LDLT, the presence of 
multiple DSAs and high PRA seem to be associated with poor 
graft outcomes, although our results did not reach statistical 
significance. Large cohort studies including mean fluorescence 
intensity (MFI) strength of each DSA are needed to clarify the 
role of pretransplant DSAs and PRA after LDLT. 
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